Reproductive Immunology and IVF: What the Science Actually Says About NK Cells

If you've spent time in IVF forums after a failed cycle, you've probably encountered the term "NK cells." Natural killer cells, immune testing, intralipid infusions, immunoglobulin therapy — these form the basis of a growing field called reproductive immunology that inspires passionate debate among fertility specialists.

Some doctors consider immune testing and treatment an important piece of the implantation puzzle. Others call it unproven and overmarketed. Both sides have legitimate points. This guide presents the evidence as it stands — honestly, without agenda.

What Are NK Cells?

Natural killer cells are a type of white blood cell that plays a role in your immune system's response to infections and abnormal cells. They circulate in your blood and are also present in the uterine lining (endometrium).

The distinction matters: blood NK cells and uterine NK cells are different populations with different functions. Blood NK cells primarily attack viruses and tumor cells. Uterine NK cells (uNK cells) play a role in implantation and early placental development — they help remodel blood vessels in the endometrium to support a growing pregnancy.

What the Evidence Shows

Testing

Blood NK cell levels: Several studies have found that women with recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) have higher peripheral blood NK cell levels. However, correlation isn't causation — elevated NK cells may be a response to pregnancy failure rather than a cause. Blood NK levels also fluctuate naturally with stress, infection, and menstrual cycle phase.

Uterine NK cell biopsy: More relevant than blood testing, as uterine NK cells are directly involved in implantation. Some clinics perform endometrial biopsies to count uNK cells. But "normal" ranges aren't well established, and the clinical significance of elevated uNK cells remains debated.

NK cell cytotoxicity assays: These measure how aggressively NK cells kill target cells in a lab dish. The assumption is that hyperactive NK cells would attack an implanting embryo. However, this assay tests blood NK cells against artificial targets — not uterine NK cells against an embryo — which limits its clinical applicability.

Treatment

Intralipid infusions (Evidence: Level 3–4): A mixture of soybean oil, glycerin, and egg phospholipids infused intravenously. The theory: intralipids suppress NK cell activity, creating a more tolerant immune environment for implantation. Several small studies suggest benefit in patients with elevated NK activity, but large randomized trials are lacking. Cost: $100–$300 per infusion in Colombia.

Intravenous immunoglobulin (IVIg) (Evidence: Level 3–4): Pooled human antibodies infused to modulate immune function. More expensive ($2,000–$5,000 per infusion in the US) and carries higher risk than intralipids. Some studies show benefit in RPL patients with immune markers; others show no effect. Not routinely recommended by mainstream fertility organizations.

Prednisone / prednisolone (Evidence: Level 3): Low-dose corticosteroids prescribed around embryo transfer to suppress immune activity. The most commonly used immune-modulating intervention in IVF, partly because it's inexpensive and low-risk. Evidence is mixed — some studies suggest marginal benefit, particularly in patients with autoimmune markers.

Tacrolimus (Evidence: Level 3–4): An immunosuppressant drug used in organ transplant medicine, prescribed by some reproductive immunologists for implantation failure. Very limited fertility-specific evidence. Higher risk profile than other options.

The Problem with Current Evidence

The reproductive immunology field suffers from several structural issues that make the evidence difficult to interpret:

• Small sample sizes: Most studies involve fewer than 100 patients, making results unreliable
• Lack of randomized controlled trials: Much of the data comes from observational studies or case series
• Publication bias: Positive results are more likely to be published than negative ones
• Non-standardized testing: Different labs use different protocols, reference ranges, and assays, making comparison across studies difficult
• Placebo effect: Patients undergoing immune treatment also receive additional monitoring and attention, which may independently improve outcomes

What Mainstream Organizations Say

The American Society for Reproductive Medicine (ASRM), the European Society of Human Reproduction and Embryology (ESHRE), and the Royal College of Obstetricians and Gynaecologists (RCOG) have all published statements noting that routine immune testing and treatment in IVF is not supported by current evidence and should not be offered as standard care.

This doesn't mean immune factors are irrelevant — it means the testing and treatments available today haven't been proven effective in rigorous trials. The organizations support further research while cautioning against widespread clinical use before evidence catches up.

A Balanced Approach

If you've experienced multiple unexplained implantation failures with chromosomally normal (PGT-A tested) embryos and adequate endometrial preparation, exploring immune factors is reasonable — as long as you go in with clear expectations:

• Immune testing may identify markers that correlate with implantation failure, but the clinical significance of those markers is uncertain
• Treatment options (intralipids, low-dose steroids) are generally low-risk and low-cost — the downside of trying is minimal
• No immune treatment is guaranteed to change outcomes
• Be cautious of practitioners who present immune testing as definitively diagnostic or immune treatment as proven

Immune Testing in Colombia

Colombian fertility clinics vary in their approach to reproductive immunology. Some offer comprehensive immune panels as part of their recurrent failure workup. Others take a more conservative approach, focusing on established factors (uterine anatomy, endometrial receptivity, embryo quality) before exploring immune hypotheses.

When immune testing is offered, it's significantly cheaper than in the US — a comprehensive panel including NK cell levels and cytotoxicity assays might cost $200–$500 in Colombia versus $1,000–$3,000 in the US. This lower cost makes it easier to include immune testing as part of an investigative workup without the financial pressure to justify expensive testing with certain treatment.